NCT06474780|Unknown
Loading search results
Sponsor study identifier
observational
900
0 countries
N/A
Study Start
June 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The study was planned as a randomized controlled study to evaluate the effect of virtual reality glasses used on anxiety and treatment compliance in outpatient cancer patients receiving chemotherapy. The sample of the study consisted of a total of 30 patients, including 15 experimental and 15 control groups, who received intravenous chemotherapy treatment every 21 days between April 1 and September 31, 2023, in the outpatient chemotherapy unit of a research hospital. Research data will be collected using the Patient Information Form, Beck Anxiety Scale (BAI) and Chronic Disease Adaptation Scale (CCDS). In evaluating the data, it was planned to analyze the differences between the rates of categorical variables in independent groups with Chi-Square tests. It was planned to use t tests to compare quantitative continuous data between two independent groups. Dependent groups t-test will be used to compare measurements within groups. After being informed about the research, patients in both groups will be given a pre-test. Patients in the experimental group will be shown 3 different videos with virtual reality glasses during 3 cycles of chemotherapy treatment, and a final test will be administered to both groups at the end of the 3rd cycle..
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 24, 2024
Actual (reported)June 26, 2024
Actual (reported)June 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Virtual Reality Glasses
Virtual Reality Glasses Used in Cancer Patients Will Reduce Anxiety Score on the Visual Analogue Scale in 3 Months
3 month
Patients were informed about the study and patients who signed the informed consent form were included in the study. A pretest was applied to the patients. In the pre-test, data were collected using the "Patient Information Form", "Adaptation to Chronic Diseases Scale" and "Beck Anxiety Scale". Patients in the experimental group were shown videos of nature walks, forest walks and city tours of their choice for 15 minutes through virtual reality glasses 1 3 times in 21 days. At the end of the 3rd time, final tests were applied.
Patients were informed about the study and patients who signed the informed consent form were included in the study. A pretest was applied to the patients. In the pre-test, data were collected using the "Patient Information Form", "Adaptation to Chronic Diseases Scale" and "Beck Anxiety Scale". No application was made to the control group for 1.3 times in 21 days. Posttests were performed at the end of treatment for the third time.
Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The population of the research consists of all individuals diagnosed with cancer who applied to a University Training and Research Hospital Outpatient Chemotherapy Unit to receive chemotherapy treatment. An average of 900 patients diagnosed with cancer are admitted to the chemotherapy unit per month. Power analysis was performed to determine the number of samples for this research. G\*Power 3.1 program was used for power analysis. In determining the power of the research, it was aimed to reach a total of 30 people, 15 people in each group, with a 95% confidence level (significance level) and an effect size of 0.90. This sample size is at an appropriate level in terms of achieving the purpose of the research and strengthening its results. Therefore, it was decided to include 15 patients in the experimental group, 15 in the control group, and 30 patients in total.
First Submitted
May 24, 2024
First Posted
June 26, 2024
Study Start
June 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 30, 2024
Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 25, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 26, 2024
Record last verified: 2024-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: